Data for review in connection with the New Drug Application to NAFDAC for use as an immune booster and adjunct treatment for Human Immunodeficiency Virus ORLANDO, FL AND DUBLIN, IRELAND / ACCESSWIRE / IMUN/ January 21, 2016 / Immune Therapeutics Inc., a U.S. public company (OTCQB: IMUN) today announced that it has completed its 90-day bridging trail of Human Immunodeficiency Virus positive [HIV+] patients and submitted data to The National Agency for Food and Drug Administration and Control, (NAFDAC) inRead more
- Cannabis Strategic Ventures and Sunniva Inc. Enter Into Cannabis Extraction Services Agreement
- Precision Therapeutics Merger with Helomics Corp. Accelerates Personalized Cancer Treatment Strategies
- Precision Therapeutics Granted European Patent for its Automated, Direct-to-Drain Medical Fluid Disposal System
- PHI Group Partners with Fintech Green Investment Company
- Third and Fourth Quarters 2018 Expected to See Continued Advancements for the Pura Natural’s Grease Beast Products Amid Approval as an Available Vendor to All True Value and Ace Hardware Stores
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More